RxDoctor Payments Data

Adam Jorgensen, MD

Glaucoma Specialist · Rapid City, SDNPI 1366700460

Payments from drug & device makers

$252,355in general payments, 2019–2025

Across 226 payments — averaging $1116.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$154K
  • AbbVie$92K
  • NEW World Medical,inc.$3K
  • US Retina LLC$3K
  • Alcon$218
  • Ivantis, Inc$168
  • plus $350 from 7 others
$28,504in research payments, 2019–2025

Across 19 payments — averaging $1500.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • NEW World Medical,inc.$29K

What the payments were for

  • Consulting fees$1503%
  • Travel & lodging$180%
  • Food & beverage$2,04142%
  • Gifts$451%
  • Ownership interest$2,63154%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$599,244
Medicare patients
1,134
Services billed
3,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate154$65,359
LumiganBimatoprost124$54,917
CombiganBrimonidine Tartrate/Timolol126$34,909
RocklatanNetarsudil Mesylat/Latanoprost67$30,133
Latanoprost1,384$11,273
Prednisolone Acetate373$10,822
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol66$10,416
RestasisCyclosporine13$8,972
Brimonidine Tartrate370$8,553
Travoprost50$7,373
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat363$6,604
Ketorolac Tromethamine367$6,443
Alphagan PBrimonidine Tartrate20$5,981
Timolol Maleate546$5,403
Ofloxacin285$3,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$92,142$104,779283 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$68$95,492221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in South Dakotaon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →